## CI: The Cigna Group - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.55 indicates fundamental undervaluation. Quality metrics strong (ROE 16%). Consistent execution (3/4 quarters beat estimates).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($261.17)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Neutral (Bullish: 2, Bearish: 2)

**1. ATTENTION CI SHAREHOLDERS: Investors Who Lost Money on The Cigna Group are Urged to Contact Levi & Korsinsky About an Ongoing Investigation**
- Source: WJTV | 20251217T120752 | Bearish | Relevance: 100%
- Levi & Korsinsky has initiated an investigation into The Cigna Group (NYSE:CI) concerning potential violations of federal securities laws. This follows Cigna's Q3 2025 earnings report, which revealed a higher Healthcare Medical Care Ratio (MCR) of 84.8% compared to 82.8% in Q3 2024, leading to a significant drop in the company's stock price by 17% on October 30, 2025. Investors who suffered losses are encouraged to contact Levi & Korsinsky for more information regarding the ongoing investigation.

**2. Does Cigna Group’s Recent Gains Reflect Its Long Term Potential In 2025?**
- Source: Simply Wall Street | 20251217T010759 | Bullish | Relevance: 100%
- This article analyzes Cigna Group (NYSE: CI) to determine if its current stock price reflects its long-term potential, suggesting it might be undervalued. Using a Discounted Cash Flow (DCF) analysis, the intrinsic value is estimated at $1,062 per share, indicating a significant 74.0% discount. Additionally, its current Price-to-Earnings (PE) ratio of 12.0x is well below industry averages, further supporting the undervaluation thesis based on its Fair Ratio framework.

**3. Does Cigna Group’s Recent Gains Reflect Its Long Term Potential In 2025?**
- Source: Simply Wall Street | 20251217T012346 | Bullish | Relevance: 100%
- Cigna Group (NYSE:CI) is currently trading at what appears to be a significant discount, with a valuation score of 5/6 and a potential 74.0% undervaluation based on discounted cash flow analysis. The stock also trades at a lower Price/Earnings ratio (12.0x) compared to the broader healthcare industry (23.9x) and its peer group (31.2x), suggesting it is undervalued given its earnings growth outlook. Investors can explore "Narratives" on Simply Wall St to understand different assumptions influencing Cigna's fair value.

**4. CI STOCK ALERT: Levi & Korsinsky Notifies The Cigna Group Investors of an Ongoing Investigation**
- Source: ACCESS Newswire | 20251215T140756 | Bearish | Relevance: 100%
- Levi & Korsinsky has launched an investigation into The Cigna Group (NYSE:CI) for potential federal securities law violations. This investigation follows CI's third-quarter 2025 earnings report, which revealed an increase in their Healthcare MCR to 84.8% from 82.8% in 2024, attributed to their Individual and Family Plans business and higher stop loss medical costs. This news led to a 17% drop in CI's stock price on October 30, 2025.

**5. Rep. Julie Johnson Sells Philip Morris International Inc. (NYSE:PM) Shares**
- Source: MarketBeat | 20251215T132136 | Neutral | Relevance: 75%
- Representative Julie Johnson (D-Texas) recently sold between $1,001 and $15,000 worth of Philip Morris International Inc. (NYSE:PM) shares on November 13th, as disclosed in a December 11th filing. She also sold similar amounts of shares in several other major companies on the same date. The article provides a financial overview of Philip Morris International, including its market performance, recent earnings, dividend announcement, and institutional investor activity, alongside analyst ratings.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 2 ($1.01M) |
| Sells | 2 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 48.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 6 / 4 |

**Top Holders:**
- Vanguard Group Inc: 9.6% (+0.1%)
- Blackrock Inc.: 8.3% (-1.1%)
- JPMORGAN CHASE & CO: 5.0% (+106.4%)
- State Street Corpora: 4.5% (-1.2%)
- Price (T.Rowe) Assoc: 4.2% (+9.8%)

### Key Risks

1. Long-term trend broken: trading 9.4% below SMA200.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Momentum building: MRS_20 improving +4.3% over 5 days suggests accumulation.

### Fundamentals

PEG ratio 0.55 indicates undervaluation relative to growth. Forward P/E 9.0x stretched relative to 3% growth. Balance sheet: $3.1B free cash flow. Insider buying signal ($1.0M), management confidence. Institutional flow bullish (6 buying vs 4 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $73.1B |
| Beta | 0.26 |
| 52W Range | $239.51 - $350.00 |
| Short Interest | 1.9% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.55 |
| Forward P/E | 9.0 |
| Current P/E | 9.2 |
| YoY Growth | 3.3% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from -1.4% to 2.9% (+4.3% in 5 days), confirming momentum buildup. Below STRENGTH zone by 1.1pp (needs >4.0% for momentum thesis). MRS_5 at 1.5% confirms short-term momentum alignment. Below SMA200 (0.91x), long-term trend not supportive. MACD histogram positive (1.28), confirming momentum. RSI neutral at 51. OFD pattern: -SUN (Resistance).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 2.93% (CS: 56) | Neutral |
| RSI_14 | 50.7 | Neutral |
| MACD Histogram | 1.28 | Bullish |
| vs SMA20 | 1.006x | Above |
| vs SMA50 | 0.981x | Below |
| vs SMA200 | 0.906x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $273.75
- **Stop Loss:** $261.17 (4.6% risk)
- **Target:** $298.91 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 85
- **Position Value:** $23,268.75
- **Portfolio %:** 23.27%
- **Risk Dollars:** $1,080.00
- **Risk Per Trade:** 1.08%
- **Modifiers:** L1 90% | L2 120% | Combined 1.08x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | RISK_OFF (HIGH) | 0.90x |
| L2 Sector | TREND (Zone A) | 1.20x |

*RISK_OFF regime with deteriorating conditions. VIX rising to 17.6 (+11.7% over 5 days) signals increasing anxiety, while narrow breadth at 52.6% indicates selective participation. AI infrastructure cost concerns are pressuring tech leadership, creating sector rotation challenges in a late-cycle environment.*

### Earnings

**Next:** 2026-02-05 (Est: $7.90)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $7.64 | $7.83 | +2.5% |
| 2025Q2 | $7.15 | $7.20 | +0.6% |
| 2025Q1 | $6.35 | $6.74 | +6.2% |
| 2024Q4 | $7.82 | $6.64 | -15.1% |

---
*RULE-based L3 | 2026-01-07 01:41 | MRS_20*